Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
Primary Objective: To determine the maximum tolerated dose of docetaxel when given with
Irinotecan and Carboplatin for the treatment of inoperable lung cancer.
Secondary Objective: To evaluate the dose-related toxicities of this triple regimen in
patients with inoperable lung cancer.